Statements of Cash Flows

for the financial year ended 31 december 2014

	Note	Group		Company	
		2014 RM'000	2013 RM'000	2014 RM'000	2013 RM'000
CASH FLOWS FROM OPERATING ACTIVITIES					
Cash receipts from customers Cash payments to suppliers and		2,150,779	1,947,477	-	179,737
employees		(1,900,696)	(1,644,064)	(13,467)	(59,479)
Cash generated from/(used in) operations		250,083	303,413	(13,467)	120,258
Interest paid		(16,573)	(16,149)	_	_
Tax paid		(21,338)	(33,578)	-	_
Interest received		1,307	1,213	-	-
Net cash generated from/(used in)					
operating activities		213,479	254,899	(13,467)	120,258
CASH FLOWS FROM INVESTING ACTIVITIES					
Acquisition of a subsidiary (net of					
cash acquired)	14	(69,264)	(4,505)	-	-
Issuance of shares by a subsidiary		186	-	-	-
Proceeds from disposal of property,					
plant and equipment		619	301	-	-
Purchase of property, plant and					
equipment	12	(31,434)	(43,514)	-	-
Purchase of intangible assets	16	(54,649)	(36,288)	-	-
Gross advances to subsidiaries		-	-	(98,116)	(23,708)
Gross repayments from subsidiaries		<u>-</u>	-	1,606	45,386
Net cash (used in)/generated from					
investing activities		(154,542)	(84,006)	(96,510)	21,678

pharmaniaga ■ 104

	Note	Group		Company	
		2014 RM'000	2013 RM'000	2014 RM'000	2013 RM'000
CASH FLOWS FROM FINANCING ACTIVITIES					
Dividends paid Drawdown of short term borrowings Interest paid Repayment of short term borrowings		(57,472) 508,154 - (510,787)	(37,187) 284,817 - (418,945)	(57,472) 65,000 (4,148) (55,000)	(37,187) 125,000 (4,635) (190,000)
Gross advances received from subsidiaries Gross repayments to subsidiaries		-		170,860 (9,893)	179,690 (214,056)
Net cash (used in)/generated from financing activities		(60,105)	(171,315)	109,347	(141,188)
NET CHANGES IN CASH AND CASH EQUIVALENTS		(1,168)	(422)	(630)	748
Foreign exchange differences		250	(1,231)	-	-
CASH AND CASH EQUIVALENTS AT BEGINNING OF FINANCIAL YEAR		32,900	34,553	1,192	444
CASH AND CASH EQUIVALENTS AT END OF FINANCIAL YEAR	22	31,982	32,900	562	1,192

The accompanying notes form an integral part of these financial statements.